The DAPA-HF and EMPEROR-Reduced trials were pivotal in demonstrating the cardiovascular benefits of SGLT2 inhibitors in terms of reduced heart failure hospitalization and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status [106,107]. Here, SLC5A2 is linked to heart failure.